Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Alto Neuroscience, Inc. during the IPO and the subsequent class period about the upcoming lead plaintiff deadline for a class action lawsuit [1][5]. Group 1: Class Action Details - Investors who purchased Alto securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 19, 2025 [3]. - The lawsuit claims that throughout the class period, defendants made materially false and misleading statements regarding Alto's business and prospects, particularly concerning the effectiveness of ALTO-100 in treating major depressive disorder [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Centene Corporation securities between December 12, 2024, and June 30, 2025, of the September 8, 2025, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Centene securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by September 8, 2025, to serve as lead plaintiff [2]. - The lawsuit alleges that Centene's management provided misleading information regarding the company's revenue guidance and earnings per share for the 2025 fiscal year, while concealing adverse facts about enrollment and morbidity rates [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [3].

Core Viewpoint - A class action lawsuit has been filed against CTO Realty Growth, Inc. for misleading statements regarding the sustainability of its dividends and financial practices during the Class Period from February 18, 2021, to June 24, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that CTO Realty Growth made false and misleading statements about the sustainability of its dividends and used deceptive practices to inflate its Adjusted Funds from Operations (AFFO) [5]. - It is alleged that the company's financial prospects were overstated, leading to investor damages when the true information was revealed [5]. Group 2: Participation Information - Investors who purchased CTO Realty securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm for more information [3][6]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Centene Corporation securities between December 12, 2024, and June 30, 2025, of the September 8, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Centene securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5] - The deadline to move the Court to serve as lead plaintiff is September 8, 2025, with the lead plaintiff acting on behalf of other class members [2] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3] - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been ranked highly for its performance in securities class action settlements [3] Group 3: Case Allegations - The lawsuit alleges that Centene's defendants provided misleading information regarding the company's expected revenue guidance and adjusted diluted earnings per share for the 2025 fiscal year [4] - Defendants reportedly made positive statements about Centene's enrollment and morbidity rates while concealing adverse facts, leading to investor damages when the truth was revealed [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Petco Health and Wellness Company, Inc. securities between January 14, 2021, and June 5, 2025, of the upcoming lead plaintiff deadline on August 29, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Petco securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by August 29, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that throughout the Class Period, Petco's management made false and misleading statements regarding the sustainability of its pandemic-related growth and the viability of its business model focused on premium pet food [5]. - It is claimed that the strength of Petco's differentiated product strategy was overstated, and the true scope of issues affecting the company was downplayed [5]. - The lawsuit asserts that these misleading statements led to an overestimation of Petco's ability to achieve sustainable, profitable growth, resulting in investor damages when the truth was revealed [5].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Lineage, Inc. common stock related to its July 2024 IPO, alleging that the registration statement was misleading and failed to disclose critical information about the company's financial health and market conditions [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Lineage was experiencing a decline in customer demand due to increased cold-storage supply and a shift in customer inventory strategies post-COVID-19, which was not disclosed in the registration statement [5]. - It is alleged that Lineage had implemented unsustainable price increases prior to the IPO, which could not be maintained in the face of weakening demand [5]. - The lawsuit asserts that Lineage was unable to counteract adverse market trends through operational efficiencies or competitive advantages, leading to stagnant or declining revenue, occupancy rates, and rent prices [5]. Group 2: Investor Information - Investors who purchased Lineage common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff is needed to represent the class, and interested parties must move the court by September 30, 2025 [1][3].

Core Viewpoint - The Portnoy Law Firm is investigating potential securities fraud claims against CS Disco, Inc. and may file a class action on behalf of investors who suffered losses [1][3]. Group 1: Investigation Details - The investigation is initiated following a class action complaint filed on September 19, 2023, covering the period from July 21, 2021, to August 11, 2022 [3]. - The investigation focuses on whether the board of directors of CS Disco breached their fiduciary duties to the company [3]. Group 2: Allegations of Misrepresentation - The complaint alleges that CS Disco highlighted strong revenue growth from its cloud-based electronic discovery platform but failed to disclose significant headwinds that could impact growth [4]. - It is claimed that the company acknowledged its rapid revenue growth was "usage driven" and potentially volatile, yet did not inform investors of any risks [4]. Group 3: Impact of Financial Results - The truth began to emerge on August 11, 2022, when CS Disco reported second-quarter 2022 financial results that fell short of expectations, revealing a significant slowdown in revenue growth [5]. - Following this news, CS Disco's stock price dropped approximately 53% on August 12, 2022, on heavy trading volume [5].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against CS Disco, Inc. due to allegations of fiduciary duty breaches by the board of directors during a specified class period [1][2]. Group 1: Allegations and Financial Impact - The class action complaint alleges that CS Disco misrepresented its revenue growth and failed to disclose significant headwinds affecting its business during the class period from July 21, 2021, to August 11, 2022 [2]. - On August 11, 2022, CS Disco reported financial results that revealed a drastic tapering of revenue growth, leading to a 53% drop in common shares on August 12, 2022, due to heavy trading volume [2]. Group 2: Legal Rights and Contact Information - Long-term stockholders of CS Disco are encouraged to contact Bragar Eagel & Squire for discussions regarding their legal rights and potential claims related to the allegations [1][3]. - The law firm offers no-cost consultations for affected investors to explore their options [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Novo Nordisk A/S securities between May 7, 2025, and July 28, 2025, of the September 30, 2025, deadline to become lead plaintiffs in a class action lawsuit [1][2]. Group 1: Class Action Details - A class action lawsuit has been filed against Novo Nordisk, alleging that the company provided misleading statements about its growth potential while concealing material adverse facts [4]. - Investors who purchased securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2]. - The lawsuit claims that Novo Nordisk overstated its potential in the GLP-1 market and the likelihood of patients switching to its branded alternatives, leading to investor damages when the true information was revealed [4]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [3]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [3]. - The firm was ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3].

Core Points - Rosen Law Firm is reminding investors who purchased Capricor Therapeutics, Inc. securities between October 9, 2024, and July 10, 2025, of the lead plaintiff deadline on September 15, 2025 [1] - Investors may be entitled to compensation through a contingency fee arrangement without any out-of-pocket costs [2] - A class action lawsuit has been filed, and interested parties can join by contacting the firm or visiting their website [3] Case Details - The lawsuit alleges that Capricor provided misleading information regarding its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [5] - Defendants allegedly made positive statements about obtaining a Biologics License Application (BLA) from the FDA while concealing adverse facts about the safety and efficacy data from the Phase 2 HOPE-2 trial [5] - The misleading information is claimed to have caused shareholders to purchase securities at inflated prices, leading to damages when the truth was revealed [5] Rosen Law Firm's Credentials - The firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has recovered hundreds of millions for investors [4] - The firm has been consistently ranked among the top firms for securities class action settlements since 2013 [4]